Replies to post #462764 on Anavex Life Sciences Corp (AVXL)

[Hosai]

P value doesn't directly measure effect size but with a p value showing 5 in 10,000 chance of the dosed groups improvement being due to chance it's more likely it's not merely a trivial improvement.

[williamssc]

Ha. No other company has reported seeing a reduction in brain volume loss because it's not happening. Mabs are seeing brain swelling and bleeding which is a problematic side effect. However how small the reduction in loss, it is an excellent outcome.

[tschussmann1]

"My question is why does Anavex just release a p-values range, but not absolute numbers of reduction in brain volume loss and by brain region?"

Fair enough. My thoughts are that the absolute differences were fairly small due to the relatively short time duration of the study. If so, this makes the resulting p-values quite remarkable. Perhaps the specifics will be included in the peer reviewed paper? I highly expect they will be included in the applications for approval.

I also expect this to be studied in the OLE, but of course without a control. If A 2-73 remains effective then the slope of brain matter loss vs time will continue to be unusually low compared to normal Az progression...

[Steady_T]

If the reduction in volume was very small given the small numbers in the trial, the P value would not be significant. I thought you would understand that.

The data released is top line data. The data you are asking for would not be released in a top line PR. Again, I thought you would know that.

That level of data you are looking for would come in a paper, peer reviewed or otherwise, but you know that.